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Abstract (<250 words) 
Purpose  
Patients with cancer frequently experience an involuntary loss of weight (in particular loss of 
muscle mass), defined as cachexia, with profound implications for independence and quality 
of life. The rate at which such patients’ physical performance declines has not been well 
established. The aim of this study was to determine the change in muscle strength and 
function over 8 weeks in patients with already established cancer cachexia, to help inform the 
design and duration of physical activity interventions applicable to this patient group. 
 
Methods 
Patients with thoracic and gastrointestinal cancer, with unintentional weight loss of >5% in 6 
months or BMI < 20 plus 2% weight loss were included. Physical and functional assessments 
(baseline, 4 weeks, 8 weeks) included: isometric quadriceps and hamstring strength, 
handgrip, standing balance, 10m walk time and timed up and go.  
Results 
Fifty patients (32 male), mean ±SD age 65 ±10 years and BMI 24.9 ±4.3kg/m2 were 
recruited. Thoracic cancer patients had lower muscle strength and function (p<0.05). Despite 
notable attrition, in patients who completed all assessments (8 thoracic and 12 
gastrointestinal) there was little change in performance over 8 weeks (p>0.05). Baseline 
variables did not differentiate between completers and non-completers (p>0.05). 
 
Conclusions 
More than a third of patients with established cancer cachexia in our study were stable over 
8 weeks, suggesting a subgroup who may benefit from targeted interventions of reasonable 
duration.  Better understanding the physical performance parameters which characterize and 
differentiate these patients has important clinical implications for cancer multidisciplinary 
team practice.  
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Background: 
Patients with cancer frequently experience cachexia, defined as weight loss greater than 
5%, or >2% in individuals with a low body-mass index (BMI <20kg/m2) in the last 6 months 
[1]. This is associated with a decline in function, daily activities and quality of life (QoL) [2]. 
However, there is very little reproducible data available on the rate and size of decline in 
muscle strength in cancer site-specific patients with established cachexia [3]. Greater 
understanding of the progression of the disease will inform the targeted intervention to 
optimise function and wellbeing. 
 
The mechanism of loss of muscle and physical function in cancer cachexia is multifactorial, 
including metabolic alterations, reduced nutritional stores and intake, and reduced activity 
[4]. Consequently there is a need for multimodal therapy to optimise patient outcomes [5]. As 
part of this approach, structured physical activity has potential to attenuate the process of 
muscle wasting in cachexia. In the advanced stages of chronic thoracic disease, exercise 
interventions are an effective means of improving muscle strength [6] and QoL [7], and there 
is evidence that programmed exercise is associated with improved outcomes in cancer 
patients undergoing active treatment [8]. 
 
Participants in studies of exercise interventions, even in advanced cancer, have been mainly 
drawn from non-cachectic populations [9]. Studies in those with advanced cancer have also 
been small in sample size and often in patients well enough to attend centres for group 
interventions [10]. For example Jensen et al’s study of resistance and aerobic training (n=21) 
was deemed feasible and improved cancer-related symptoms in gastrointestinal (GI) cancer 
patients undergoing palliative chemotherapy, but the degree of cachexia was not defined  
[11]. Oldervoll et al’s study of a group exercise intervention in palliative patients (n=34) 
showed potential for benefit, but highlighted issues of attrition, adherence and type of 
exercise [12].  
This may have implications for multidisciplinary anticancer treatment planning and creates 
uncertainty in implementing structured physical activity interventions in clinical settings, with 
a lack of understanding for example of what duration of intervention might be feasible. From 
a clinical research perspective it also creates significant difficulty in estimating statistical 
power for  pragmatic studies of physical activity interventions,, particularly in a 
heterogeneous population where standard deviation may be wide [13]. 
Identifying which patients with established cachexia are likely to tolerate targeted, 
longitudinal interventions to increase physical activity will increase compliance and reduce 
attrition, resulting in more patient-appropriate clinical treatment options [14]. 
The aim of this study, therefore, was to determine the size and rate of decline of muscle 
strength, balance and physical function, and the rate of attrition, in a patient population with 
established cancer cachexia. Muscle strength was assessed as maximal application of 
muscle force, physical function was assessed by 10m walk velocity and the timed up and go 
test (TUG). We also aimed to identify relationships between performance status, physical 
function and measures of strength and balance. 
Methods 
Participants  
Participants were part of a larger study evaluating, self-confidence, perceived control as well 
as exercise preferences and motivations in patients with established cancer cachexia [14].  
Of the 104 patients (45 thoracic and 59 GI) recruited at the two local sites, 50 patients were 
recruited from lung cancer, GI cancer or palliative care clinics in Cardiff between September 
2011 and December 2013. Adults with unintentional, self-reported or recorded weight loss of 
>5%, or a BMI of <20 and any weight loss in the preceding 6 months were recruited from two 
outpatient clinics. Patients with a life expectancy of less than 8 weeks were excluded from 
the study as were those with musculoskeletal or neurological disorders which would 
compromise mobility or balance, e.g. Parkinson’s disease, cerebrovascular accident or 
anatomical abnormality. The study was approved by the South East Wales Ethics 
committee, Cardiff and Vale University Health Board and Velindre R&D was obtained. All 
participants gave written informed consent. 
 
Assessments 
Assessments were completed by a trained researcher in a standardised manner in a home 
or clinical setting based on patient preference. At baseline, patients’ cachexia status, 
demographic variables, disease stage and Karnosfsky performance score were recorded.  
The Karnosfsky Performance Scale is widely used to quantify the functional impairment in 
cancer patients with a score from 0 to 100, where 100 reflects normal functioning and health. 
The trained researcher explained the scale and asked patients to indicate which statement 
described their current ability [15]. The self assessed Karnofsky performance score was 
captured at baseline only in the context of a larger study where patients self-reported current 
and previous exercise levels. Motivational factors for physical activity were also examined 
[14]. The limitations of clinician reported performance status are well documented, with inter-
observer variability between healthcare professionals [16] and also between clinicians and 
patients [17]. Clinicians tend to overestimate performance status, and where there is 
disagreement, patient reported performance status may more accurately correlate with 
survival [18]. We therefore felt it appropriate to use a patient reported measure in our study, 
whilst acknowledging the limitation of not having longitudinal data capture. 
Longitudinal assessments, on initial visit, 4 and 8 weeks (+/- one week), were: BMI, muscle 
strength, balance and physical function including the 10m walk and the timed up and go 
(TUG). Maximal isometric knee extensor and flexor force (Newtons) was assessed in the 
dominant leg, in a seated position using an externally fixed force gauge (JTech Medical, Salt 
Lake City, UT). Knee flexor and extensor moment (turning effect produced by a force) was 
calculated by multiplying the perpendicular force by the distance from the knee joint and 
expressed as Newtons. Handgrip strength (Takei Dynamometer 5001) was measured twice 
in both hands with the mean used for analysis. Both were compared to normative data [19]. 
The Biodex Biosway (IRPS, Suffolk) was used to assess the ability to balance on firm 
surface situations with open eyes. A static sway index score was determined, with lower 
scores indicating greater stability. Dynamic stability was assessed by challenging patients to 
shift and control their center of gravity through an interactive timed balance game. Scores 
are expressed as a % with higher scores indicating greater stability. Acceptable reliability 
has been demonstrated with an intraclass correlation coefficient of 0.81 [20]. 
The time to walk 10m was also measured and used to calculate walking velocity [21] and the 
timed 'Up & Go' (TUG) test is a measure of task performance. Using standardised 
instructions the time taken for the participant to rise from a standardised armchair, walk 3 
metres, turn and walk back to the seat was be recorded using a stopwatch [22].  
 
Statistical Analysis 
Descriptive results at each time point are presented as means ± standard deviation and 
median interquartile range (IQR) for nonparametric data. We aimed to recruit 50 participants 
taking part in a larger questionnaire study of motivation and preferences in relation to 
structured physical activity [23]. Baseline analysis included independent t tests, Mann 
Whitney U tests (nonparametric data) or the Chi Square test (ordinal data). Spearman’s Rho 
(rs) was used to evaluate the relationship of functional impairment (using Karnofsky scores), 
and demographic variables with muscle strength, task performance and balance. Repeated 
measures analysis of longitudinal data was undertaken using the Friedman test. 
 
 
Figure 1: Flow diagram of assessments at baseline (Visit 1), four weeks (Visit 2) and eight 
weeks (Visit 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Twenty-five patients (16 male) with GI and 25 patients (16 male) with thoracic cancer. 
Amongst the thoracic patients, 22 had non-small cell carcinoma, 2 had mesothelioma and 1 
had small cell carcinoma. In the GI group 16 had upper GI malignancy and 9 had large 
bowel malignancy.  
 
Baseline results  
Self-reported Karnofsky scores did not differ between thoracic or GI patients, with most 
patients reporting themselves to be 70 or above (i.e. some limitations but mainly self-caring) 
(Table 1). Although groups were similar in mean BMI, unexpectedly the majority of thoracic 
and GI patients had BMI in or above the healthy (BMI >20 kg/m2) range. Only 16% of 
thoracic patients and 12% of GI patients had low BMI (<19.9Kg/m2) and there was a trend 
for more GI patients being in the overweight range (BMI>25 Kg/m2) (Table 1). 
n=10 Withdrawn 
n=3 Deceased 
Visit 2 
n=15 
Visit 2 
n=12 
n=8 Withdrawn 
n=2 Deceased 
n=1 Withdrawn 
n=2 Unavailable  
n=1 Deceased 
n=2 Withdrawn 
n=1 Unavailable 
Visit 3 
n=8 
Visit 3 
n=12 
Gastrointestinal 
Visit 1 
n=25 
Thoracic 
Visit 1 
n=25 
The majority of patients (88% thoracic and 96% GI) were able to complete the assessments 
of strength and physical function at baseline, despite their disease status. With the exception 
of age, body mass and BMI, data are median interquartile range (IQR) due to the non-
normal distribution.  
Thoracic cancer patients, who were slightly older on average, had poorer quadriceps 
strength, and poorer task performance in the 10m walk and TUG compared to their GI 
counterparts (All p<0.05). When examining the group as a whole, the Karnofsky score 
correlated with walking velocity (rs= 0.406) and dynamic balance (rs= 0.545) (both p<0.05). 
There was a similar relationship between Karnofsky and dynamic balance when the group 
was divided into patients with thoracic and GI cancer (Table 2). There was no difference in 
the relationships between groups, and when assessed in each group alone and the 
relationship between Karnofsky and walking velocity did not reach significance (p>0.05), 
most likely due to reduced power.  Although both walking velocity and TUG related to 
hamstring force, quadriceps force and handgrip strength, the relationship between TUG and 
self-reported Karnofsky score did not reach significance (p=0.86). 
There was no difference in age, BMI, balance, walking velocity or TUG between males and 
females. As expected body mass, lower limb and handgrip strength were greater in males 
than females (p<0.05) (Supplementary data). 
Longitudinal Results  
Twenty-seven patients (54%) completed the 4-week assessment (12 thoracic and 15 GI) 
and 20 participants (40%) completed the 8-week assessment (8 thoracic and 12 GI). Of 
these one did not attend the 4-week assessment, thus 19 patients were included in the 
longitudinal analysis (Figure 1). 
Six patients died within the eight-week period; three were lost to follow-up and 21 withdrew. 
Reasons for withdrawal included ‘feeling too unwell’, ‘too fatigued’ or ‘other time 
commitments’ while a number declined to give a reason.  
Although it was expected that strength and performance measures would decline over time, 
there was no change compared to baseline in those who completed the 4 and 8 week 
assessments (n=19), except for a statistically significant difference in 10m walking velocity 
(Table 3). However, the clinical relevance may be limited and there were no other 
differences in any of the variables in whole group (p>0.05) or the thoracic and GI sub-groups 
separately (p>0.05) (data not displayed). 
 
Differences between completers and non-completers were examined for a number of 
variables at baseline to identify potential predictors for future investigation. There were no 
differences in gender proportions, degree of weight loss at study presentation, time since 
diagnosis, BMI or muscle strength or performance measures between completers and non-
completers of the physical assessments at eight weeks (p<0.05).  
 
Discussion 
In patients with loss of muscle mass, there appears to be a non-linear relationship between 
the degree of muscle loss and reduction in strength and function [24]. For patients with 
established cancer cachexia, the rate at which functional decline occurs in site-specific 
cancer patients is unclear. Better understanding of functional changes in this defined group 
would allow more targeted interventions in those most likely to tolerate a structured activity 
programme.  
In the present study two patient groups were chosen, both of which have a high prevalence 
of cachexia [25], to allow exploratory comparison across cancer types over an 8 week 
period, particularly in relation to task performance, strength and study attrition. At baseline 
although self-reported performance based on Karnofsky scores were similar in both groups, 
there was significantly poorer task performance in the thoracic cancer patients. This may 
reflect an older population and different co-morbidity profile, and emphasises the need for 
caution in assuming a uniform effect of cachexia across site-specific cancer types and, by 
extension, the impact of specific interventions. 
The physical assessment component of the study provided several important results. 
Although both cancer groups are traditionally associated with high rates of cachexia, BMI 
was higher than might be expected in both groups. Two thirds of thoracic cancer patients 
were in the normal BMI range despite weight loss and almost half of the GI patients were in 
the overweight or obese BMI category. Although the mean BMI was in the healthy range, 
baseline assessments revealed lower muscle force than normative values [26]. This 
highlights the limitations of BMI as a defining characteristic and raises concerns about the 
potential impact of a hidden loss of muscle mass and sarcopenic obesity [27].   
Examination of the relationship between variables confirmed a positive correlation between 
the self-reported Karnofsky performance status scale and the objective measure of walking 
velocity. This demonstrates the potential utility of a simple, objective performance related 
measure rather than measures of muscle strength that did not relate to Karnofsky 
performance. The lack of relationship between the Karnofsky score, handgrip and TUG may 
be explained by small numbers. Alternatively, it may be that ambulatory activities are more 
sensitive to perceived performance in this patient group. This is supported by a relationship 
between walking capacity and performance status which has been shown [28]. 
The 10m walk test and TUG both related to lower limb force, handgrip strength and static 
balance and thus represent integrated measures of function. The finding that a simple and 
easily replicated assessment of physical performance - the ten-metre walk test and TUG - 
more closely correlated with perceived functional limitations than strength alone is promising 
and highlights both its potential utility as an outcome measure and the importance of 
assessing task performance rather than strength alone. Walking speed is a valid, and 
sensitive measure for assessing and monitoring functional status in a range of populations, 
and further exploration of specific walk speed cut off values is warranted in larger cancer 
cachexia populations [29].  
In this study the Karnofsky score was self-reported by patients, rather than physician rated 
which is common in clinical practice. A previous study identified only a moderate correlation 
between self-reported and physician rated performance score [17], with some patients 
reporting a poorer performance using the Eastern Co-operative Oncology Group (ECOG) 
score than physicians, therefore this may have affected the results.  
The 19 patients who completed all three assessments demonstrated a non-significant 
decline in knee extensor force but other physical and functional characteristics, including 
BMI, TUG, balance and handgrip were stable. The lack of deterioration over time was 
unexpected and is interpreted with caution given the degree of attrition. However, it aligns 
with findings by Prado et al [30] of residual anabolic potential even in advanced cancer. 
It also reflects findings from a previous study in patients with advanced GI cancer, which 
included 16 patients with over 3% weight loss. This study found no significant changes in 
weight, BMI, upper limb skinfold thickness or Karnofsky performance status, over a six to 
eight week period of observation [31].  
This suggests that there may be a subgroup of cachectic patients who are relatively stable 
over time, and who may tolerate a targeted intervention to increase physical activity and 
maintain function. Identifying this group would be key in administering patient-appropriate 
interventions in line with personalised patient care [32]. It also emphasises the importance of 
control groups in future intervention studies where maintaining performance or reducing the 
rate of decline is the outcome under examination.  
The degree of attrition experienced over time in this study is similar to that reported in other 
palliative studies [33,34] and demonstrates the challenges of recruiting patients and retaining 
individuals within longitudinal research in this patient group. This was despite dedicated 
resource to follow patients up in their place of choice. The baseline and longitudinal 
measures, and their standard deviations, will also add to the knowledge base in defining 
future sample sizes. 
It is disappointing that we were unable to identify a difference in characteristics between 
completers and non-completers. This is likely to relate to the small sample size. Given their 
association with other aspects of function the study does however identify simple 
performance measures (ten metre walk speed, TUG) which are worthy of further 
investigation, in addition to obvious targets such as degree of weight loss. The high rate of 
task completion at baseline and follow up is reassuring in terms of feasibility and 
acceptability of task performance measures in clinical settings. 
Conclusion 
Exercise, as a broad therapeutic strategy, has demonstrated efficacy in the earlier stages of 
cancer, reducing rates of functional decline and improving quality of life [35]. However, most 
exercise studies in cancer have recruited patients based on their disease stage rather than 
any defined impact of their cancer, with often no consideration of the degree of weight loss 
or other cachexia associated factors [9]. Where this has been reported, patients with 
established cachexia have been in the minority [36] contributing to the lack of evidence on 
benefit.  
This study represents a step forward in using reliable criteria [37] for defining a population of 
increasing interest and exploring factors of relevance in this group to inform future feasibility 
testing and sample size. The study was exploratory in nature with a relatively small sample 
size, with resultant limitations in interpreting the data. However, strengths include the 
recruitment of participants with a clear definition of cancer cachexia, and the assessment of 
more than one cancer type with a high rate of cancer cachexia, which increases the 
generalisability of the study.   
The findings highlight the potential utility of measures of task performance, easily undertaken 
in clinical settings, as outcomes reflective of perceived functional ability and the need to 
investigate – in a larger study population – baseline predictors of functional stability and 
rehabilitation potential in the setting of established cachexia. Combining such data with the 
attitudinal and motivational findings of our larger patient cohort reported elsewhere will 
benefit the development of interventions, which are acceptable and feasible in this patient 
group.  
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Table 1 Baseline Characteristics in Patients with Thoracic and Gastrointestinal (GI) Cancer 
 
Thoracic 
n=25 
GI 
n=25 
p= 
Age (years) 68.4 ± 8.4 62.4 ± 10.8 0.033 
Karnofsky score 70.0 (60.0-75.0) 70.0 (70.0-80.0) 0.138 
Body Mass (kg) 69.0 ± 19.0 74.5 ± 12 0.232 
BMI (kg/m2 ) 24.2 ±5.1 25.5 ±3.2 0.320 
BMI <19.9 
BMI 20-24.9 
BMI 25-29 
BMI>30 
n=4 
n=15 
n=3 
n=3 
n=3 
n=2 
n=12 
n=8 
 
Hamstrings (Newtons) 101.0 (65.4-130.4)b 118.8 (83.2-178.0)b 0.066 
Quadriceps (Newtons) 169.1 (115.7-213.6)b 201.6 (163.3-275.9)b 0.046 
Handgrip (kg) 23.5 (19.3-29.5)a 28.0 (16.5-34.8)a   0.337 
Static balance (SI) 0.5 (0.4-0.7)a 0.4 (0.3-0.5) 0.062 
Dynamic balance % 51.0 (40.3-57.3)d 57.0 (43.8-62.5)c 0.262 
10M walk (secs) 9.9 (8.6-12.6)c 8.7 (7.4-10.2) 0.023 
10M velocity(m/s) 1.0 (0.8-1.2)c 1.2 (1.0-1.4) 0.023 
TUG (secs) 11.9 (9.9-13.7)b 9.4 (7.8-10.8) 0.001 
Data are mean ± SD or median (IQR), missing data a=24, b=23, c=22 d=20 
BMI = Body Mass Index; SI= stability index, TUG = Timed Up and Go;  
p<0.05 significant difference between groups  
 
 
Table 2 Relationship between Karnofsky Performance Status and Baseline Variables in 
Patients with Thoracic and Gastrointestinal (GI) Cancer individually and All Patients 
 Thoracic p GI p all p=  
Age (years) -0.006 0.978 -0.327a 0.119 -0.310 0.030 
BMI (Kg/m2) -0.076 0.716 -0.080a 0.709 0.009 0.950 
Hamstrings 
(Newtons) 0.216b 0.322 0.131c 0.562 0.198 0.193 
Quadriceps 
(Newtons) -0.050b 0.822 0.192c 0.393 0.137 0.370 
Handgrip (kg) 0.312a 0.138 -0.058b 0.791 0.099 0.508 
Static balance (SI) -0.009a 0.966 0.272a 0.020 0.061 0.683 
Dynamic balance 
% 0.500
e
 0.025 0.503d 0.198 0.545 <0.001 
10M velocity(m/s) -0.398c 0.066 -0.319a 0.128 -0.406 0.005 
TUG (secs) -0.264b 0.224 -0.080a 0.709 -0.253 0.086 
Missing data a=24, b=23, c=22, d=21, e=20,  
BMI = Body Mass Index; SI= stability index, TUG = Timed Up and Go; 
 p<0.05 significant relationship 
 
 
 
Table 3 Longitudinal Assessments in Patients who completed all 3 Assessments 
 
Baseline 
n=19 
Visit 2 
n=19 
Visit 3 
n=19 
p= 
Gender male:female 12:7 - - - 
Age (yrs) 63.4 ±10.1 - - - 
BMI (Kg/m2) 25.6 (22.7-27.3) 25.5 (22.7-28.3) 24.8 (22.9 -27.3) 0.510 
Hamstrings (Newtons) 133.6 (86.1-181.1) 135.8 (86.9-172.6) 124.7 (66.2-162.5) 0.160 
Quadriceps (Newtons) 249.4 (161.5-300.7) 247.6 (170.8-324.4) 204.9 (122.5-317.7) 0.577 
Handgrip (kg)a 26.4 (17.1 -34.8) 28.6 (17.1-34.6) 26.8 (15.7-36.1) 0.270 
Static balance (SI) 0.5 (0.3-0.7) 0.4 (0.3-0.7) 0.4 (0.3-0.6) 0.500 
Dynamic balance (%)b 54.5 (49.0-64.8) 57.5 (49.8-62.3) 58.0 (43.8-67.0) 0.760 
10M velocity (m/s) 1.1 (0.9-1.3) 1.2 (0.9-1.3) 1.2 (1.1-1.5) 0.031 
TUG (secs) 9.9 (8.6-13.3) 10.3 (8.6-13.1) 9.7 (8.3-12.6) 0.230 
Data are mean ± SD or median (IQR), missing data, a=17, b=16  
BMI = Body Mass Index; SI= stability index, TUG = Timed Up and Go;  
p<0.05 significant difference  
 
 
Supplementary data 
Baseline Characteristics in Males and Females 
 
Male 
n=32 
Female 
n=18 p= 
Age (years) 65.5 ±10.7 64.9 ±9.6 0.830 
Karnofsky score 70 (60-80) 70 (60-80) 0.711 
Body Mass (kg)  73.3 ±14.7 69.7 ±17.4 0.019 
BMI (Kg/m2) 24.4 ±4.1 25.9 ±4.7 0.266 
Hamstrings (Newtons) 126.9 (98.0-171.4)b 89.1 (66.9-111.4)e 0.006 
Quadriceps (Newtons) 207.1 (124.3-282.8)b 173.7 (106.9-209.4)e 0.092 
Handgrip (kg) 29.0 (25.5-36.3)b 16.0 (12.9-20.6) <0.001 
Static balance (SI) 55.5 (47.5-60.3)a 48.0 (36.5-60.5) 0.186 
Dynamic balance % 0.4 (0.3-0.5)c 0.5 (0.4-0.7)d 0.099 
10M walk (secs) 8.8 (7.5-10.8)b 9.8 (8.5-12.2)e 0.226 
10M velocity(m/s) 1.1 (0.9-1.3)b 1.0 (0.8-1.2)e 0.235 
TUG (secs) 9.9 (8.8-12.2)b 10.4 (8.8-13.3)d 0.501 
Data are mean ± SD or median (IQR) missing data a=30, b=31, c=30 c=25, d=17, e=16 
BMI = Body Mass Index; SI= stability index, TUG = Timed Up and Go;  
p<0.05 significant difference between males and females  
